Starting with our lead drug candidate 2-73, we reported positive topline results from the second randomized placebo-controlled AVATAR phase three study for the treatment of adult patients with Rett syndrome. The study met its primary and secondary efficacy, and safety end points with consistent and clinically meaningful improvements in all efficacy measures of Rett syndrome symptoms. Convenient once daily oral liquid doses of up to 30 mg of ANAVEX 2-73 were also well-tolerated with good medication compliance. Based on the results of the AVATAR phase three study, and the prior successful U.S.